(B1) The principal physical quantities used by the Commission are the activity of an amount of radionuclide and the absorbed dose from radiation in matter. The absorbed dose is weighted for radiological protection purposes, resulting in a number of relevant dosimetric quantities. (B2) Activity: The activity, A, of an amount of a radionuclide is de®ned as (ICRP 1991a, paragraph 37): `The average...

Abstract Background Metastases to the bones are a frequent location of metastasis in advanced breast cancer and responsible for substantial morbidity healthcare expenses. Imaging has been crucial directing patient therapy decades, contributing staging response evaluation skeleton. This research aimed assess diagnostic value whole-body magnetic resonance imaging with diffusion-weighted added rad...

Prostate cancer is a growing public health problem. The palliation of pain in patients with painful bone metastases is of primary importance in the clinical management of advanced cancer. Internal therapy with radionuclides, which concentrate at sites of increased bone turnover, is used to control pain and improve quality of life as an alternative to conventional therapies. In the present study...

Radionuclide therapy aims to treat malignant diseases by systemic administration of radiopharmaceuticals, often using carrier molecules such as peptides and antibodies. The radionuclides used emit electrons or alpha particles as a consequence of radioactive decay, thus leading to local energy deposition. Administration to individual patients can be tailored with regards to the risk of toxicity ...

PULMONARY UPTAKE OF MDP Radionuclide bone scanning is now a standard technique in the staging of many malignancies. Probably the most frequent application is in screening patients with known primary malignancy and potential bone metastases. In primary malignant bone tumours, bone scanning is also useful with images often showing the lesion to be more extensive than was suspected from radiograph...

UNLABELLED An object-oriented software system is described for estimating internal emitter absorbed doses using a set of computer modules operating within a personal computer environment. The system is called the Radionuclide Treatment Planning and Absorbed Dose Estimation System (RTDS). It is intended for radioimmunotherapy applications, although other forms of internal emitter therapy may als...

introduction: bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188re-hydroxyethylidene diphosphonate (188re-hedp) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of 2.1 mev with a 15% γ-c...

Systemic therapy using bone-seeking radiopharmaceuticals has clear advantages for the treatment of multisite metastatic pain. Evidence supporting the use of beta-particle, electron, and alpha-particle-emitting radiopharmaceuticals is reviewed here. Appropriate patient selection relies on correlating clinical symptoms with focal abnormalities on conventional bone scintigraphy. Time to symptom re...